Aptose Biosciences Inc. (APTO) Stock Price Up 2.7%
Shares of Aptose Biosciences Inc. (NASDAQ:APTO) rose 2.7% during mid-day trading on Tuesday . The stock traded as high as $2.32 and last traded at $2.26, with a volume of 54,874 shares traded. The stock had previously closed at $2.20.
APTO has been the subject of several recent research reports. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Aptose Biosciences in a report on Thursday, June 9th. Canaccord Genuity reiterated a “buy” rating and set a $7.00 price objective on shares of Aptose Biosciences in a report on Thursday, June 9th. Roth Capital upgraded Aptose Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $4.00 to $8.00 in a report on Monday, June 13th. Royal Bank Of Canada reiterated an “outperform” rating and set a $23.00 price objective on shares of Aptose Biosciences in a report on Monday, June 13th. Finally, Zacks Investment Research lowered Aptose Biosciences from a “hold” rating to a “sell” rating in a report on Monday, July 11th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $12.30.
The company’s market cap is $26.88 million. The firm’s 50-day moving average is $2.46 and its 200-day moving average is $2.63.
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.